Remoxipride in the treatment of levodopa-induced psychosis

Journal of Clinical Psychopharmacology

Volumn 16, Issue 5, 1996, Pages 395-399

  Sandor, Paul ^a,c   Lang, Anthony E ^a   Singal, Sarah ^a   Angus, Carmella ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b Astra Pharma Inc   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; REMOXIPRIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; RIGIDITY; TREMOR;

AGED; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MOTOR SKILLS; PARKINSON DISEASE; PSYCHOSES, SUBSTANCE-INDUCED; REMOXIPRIDE;

EID: 0029843329     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199610000-00009     Document Type: Article

References (32)

1. Barbeau A. L-dopa therapy in Parkinson's disease: a critical review of nine years experience. Can Med Assoc J 1969;101:59-68.
2. Damasio AR, Lobo-Antunes J, Macedo C. Psychiatric aspects in Parkinsonism treated with L-dopa. J Neurol Neurosurg Psychiatry 1971;34:502-7.
3. McDowell FH, Markham CH, Lee JE. The clinical use of levodopa in the treatment of Parkinson's disease. In: McDowell FH, Markham CG, eds. Recent advances in Parkinson's disease. Philadelphia: F.A. Davis, 1971:46-52.
4. Regis E. Precis de psychiatrie. Paris: Gaslon Diox, 1906:684.
5. Patrick HT, Lery DM. Parkinson's disease: A clinical study of one hundred and forty-six cases. Arch Neurol Psychiatry 1922;7:711-20.
6. Jackson JA, Free GBM, Pike HV. The psychic manifestations in paralysis agitans. Arch Neurol Psychiatry 1923;10:680-4.
7. Mjones H. Paralysis agitans: a clinical and genetic study. Acta Psychiatr Neurol Scand Suppl 1949;54:1-195.
8. Mindham RHS. Psychiatric symptoms in parkinsonism. J Neurol Neurosurg Psychiatry 1970;33:188-91.
9. Rondot P, de Reconds J, Coignet A, Ziegler M. Mental disorders in Parkinson's disease after treatment with L-dopa. In: Hassler RG, Christ JF, eds. Advances in neurology. New York: Raven Press, 1984:259-68.
10. Goodwin FK. Psychiatric side effects of levodopa JAMA 1971; 218:1915-20.
11. Celesia GG, Barr AW. Psychosis and other psychiatric manifestations of Ievodopa therapy. Arch Neurol 1970;23:193-200.
12. Sweet RD, McDowell FH, Ferguson JS. Mental symptoms in Parkinson's disease during chronic treatment with levodopa. Neurology (Minn) 1976;26:305-10.
13. Lieberman AN, Goldstein M, Gopinathan G, Neophytides A. D-1 and D-2 agonists in Parkinson's disease. Can J Neurol Sci 1987;14: 466-73.
14. Friedman JH. The management of the levodopa psychoses. Clin Neuropharmacol 1991;14:283-95.
15. Ogren SD, Hall H, Kohler C, Magnusson O, Lindbom O, Ängeby K, Florval L. Remoxipride, anew potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol 1983;102(3.4):459-74.
16. Widerlov E. Remoxipride: a potential antipsychotic drug with selective dopamine D2 receptor properties. Clin Neuropharmacol 1984;I(S1):554-5.
17. Lewander T, Westerbergh SE, Morrison D. Clinical profile of remoxipride - a combined analysis of a comparative double-blind multicentre trial program. Acta Psychiatr Scand 1990;82[suppl 358]:92-8.
18. Lapierre YD, Ancill R, Awad G, Bakish D, Beaudry P, Bloom D, Chandrasena R, Das M, Durand C, Elliott D, Horn E, Jones B, Manchanda R, Max P, McClure DJ, Ravindran A, Rotstein E, Sandor P, Saxena B, Sladen-Dew N. A dose-finding study with remoxipride in the acute treatment of schizophrenic patients. J Psychiatry Neurosci 1992;17:135-45.
19. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10:799-812.
20. Guy W. ECDEU assessment manual for psychopharmacology, revised 1976. Washington DC: US Department of Health, Education and Welfare, 1976:76-338.
21. Fahn S, Elton RL, and members of the UPDRS development committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden GD, Goldstein M, Calne DB, eds. Recent developments in Parkinson's disease. New York: MacMillan, 1987: 153-63.
22. Folstein M, Folstein S, McHugh P. "Mini mental state" - a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
23. Colton T. Statistics in medicine. Boston: Little, Brown and Co., 1974.
24. 23a. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
25. 23b. Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson IML, eds. Third symposium on Parkinson's disease. Edinburgh: Livingstone, 1969:152-7.
26. Mendis T, Mohr E, George A, Rusk IN, Grap P, Grimes DJ. Symptomatic relief from treatment-induced psychosis in Parkinson's disease: an open-label pilot study with remoxipride. Mov Disord 1994;9:197-200.
27. Bennett JP, Landow ER, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease. D. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 1993;43:1551-5.
28. Scholtz E, Dichgans J. Treatment of drug-induced exogenous psychosis in Parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatry Neurol Sci 1985;235:60-4.
29. Wolk SI, Douglas CJ. Clozapine treatment of psychosis in Parkinson's disease: a report of five consecutive cases. J Clin Psychiatry 1992;53:373-6.
30. Philpott NJ, Marsh JCW, Gordon-Smith EC, Bolton JS. Aplastic anemia and remoxipride. Lancet 1993;342:1244-5.
31. Laidlaw ST, Snowden J, Brown MJ. Aplastic anemia and remoxipride. Lancet 1993;342:1245.
32. Murphy PT, Sivakumaran M, Ghosh K, Bricknell S, Hartley GM, Wood JK, Chapman CS. Cytopenia and remoxipride. Lancet 1994; 343:352-3.